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increase the PPV to 0.59 if the result is positive, or yield an accep-
table 1-NPV of 0.004 if the test is negative, and thus provides
important information to the clinician attempting to make a dif-
¢cult decision. Selective use in settings where the decision to
biopsy may result in an adverse patient outcome may be a poten-
tial use for computerized digital dermoscopy.
When assessing the clinical relevance of diagnostic technology,
clinicians must consider a test’s PPV and 1-NPV (not just its sen-
sitivity and speci¢city) and the pre-test probabilities where its use
may inform clinical decisions. Whereas Rubegni et al’s tool ap-
pears to be a powerful diagnostic aid, whether the additional
amount of clinical information the tool provides justi¢es the cost
of technology requires us to consider the broad determinants of
medical decision-making: physician behavior, disease prevalence,
outcome, cost, and values.
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Active Human Herpesvirus 6 Infection in a Patient with Drug
Rash with Eosinophilia and Systemic Symptoms
To the Editor:
Clinical and biologic manifestations of drug rash with eosinophi-
lia and systemic symptoms (DRESS) are well characterized and
mimic viral infection: high fever, facial edema, erythroderma fol-
lowed by an exfoliative dermatitis, di¡use lymphadenopathy, hy-
pereosinophilia, atypical circulating lymphocytes, abnormal
results of liver function tests. Other systemic manifestations may
occur (e.g., pneumonitis, pancreatitis, neurologic symptoms).
This drug adverse reaction was ¢rst described with anticonvulsi-
vants but minocycline is also well known to induce this kind of
reaction (Disdier et al, 2001).
The role of viral infection in the development of this drug
adverse reaction is suspected. We implicated for the ¢rst time
human herpesvirus 6 (HHV-6) infection in a patient with pheno-
barbital-induced DRESS complicated by a fulminant hemopha-
gocytic syndrome (Descamps et al, 1997). In a small prospective
series of seven consecutive patients hospitalized with DRESS
we demonstrated serologic evidence of HHV6 active infection
(Descamps et al, 2001). But evidence of viremia, which is the
main criterion for con¢rmation of active infection, was not de-
monstrated in these cases (Descamps and Mahe, 2002; Tohyama
and Hashimoto, 2002). Recently, we and others reported HHV-
6 encephalitis associated with DRESS (Descamps et al, 2003).We
report here a typical case of DRESS associated with minocycline
and bring evidence of viremia by quanti¢cation of HHV-6 DNA
in serum samples.
A black 25-y-old patient was prescribed minocycline for the
treatment of folliculitis on the scalp on the 16 May 2000. Seven
weeks later on the 7 July 2000 he developed an erythroderma and
Table I. Bayes’ theorem output: relation between pre-test
probability, PPV, and 1-NPV for a new melanoma digital
dermoscopic analysis
Pre-test probability PPV 1-NPV
0.01 0.11 0.0008
0.05 0.40 0.004
0.10 0.59 0.01
0.15 0.69 0.01
0.20 0.76 0.02
0.25 0.81 0.02
0.30 0.85 0.03
0.35 0.87 0.04
0.40 0.90 0.05
0.45 0.91 0.06
0.50 0.93 0.07
0.55 0.94 0.08
0.60 0.95 0.10
0.65 0.96 0.12
0.70 0.97 0.15
0.75 0.97 0.18
0.80 0.98 0.23
0.85 0.99 0.30
0.90 0.99 0.40
0.95 0.99 0.59
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was hospitalized 5 d later. On examination he had an edema of
the face, erythroderma with exfoliative dermatitis, and di¡use
lymph node enlargement. Laboratory studies showed on admis-
sion a leucocytosis (18.2109 per liter) with many large atypical
basophilic lymphocytes (48.2%) with T phenotype CD3þ (96%),
CD4þ (87%), CD7þ (70%), CD38þ (56%), CD25þ (22%),
CD19þ (1%). Three days later appeared an eosinophilia
(1.33109 per liter). Four days later after the admission alanine
aminotransferase (223 U per liter, NRo56) and aspartate amino-
transferase (314 U per liter, NRo56) concentrations increased
and then returned to normal values. Histologic examination of
skin lesions revealed a dense dermal in¢ltrate with pleomorphic
lymphocytes and atypical cells. HHV-6 infection was studied on
serum samples collected on admission (13 July) and at di¡erent
times after admission (24 July, 2 August). No treatment was given
during this period. The presence of anti-HHV-6 IgG and IgM
antibodies was determined at the same time in the di¡erent ser-
um samples using an indirect immuno£uorescent antibody assay
(Descamps et al, 1997). Anti-HHV-6 IgG serologic tests revealed a
rise in the antibody titer from 80 (13 July) to 640 (2 August). Pre-
sence of anti-HHV-6 IgM was only demonstrated in the ¢rst
serum (13 July). A polymerase chain procedure and a real-time
HHV-6 quantitative PCR assay were performed on the serum
samples (Desachy et al, 2001; Collot et al, 2002). Detection of
HHV-6 DNA was positive on the ¢rst two serum samples (13
July and 24 July) and was quanti¢ed at 16,909,880 copies per ml
and 8400 copies per ml, respectively. It was negative in the third
serum. Genotyping of HHV-6 indicated a type B genotype. Ser-
ologic investigations for coxsackies A and B, echovirus, HIV, and
cytomegalovirus infections were negative. Serologic data sup-
ported previous infection with Epstein-Barr virus, toxoplasmosis,
and parvovirus B19.
DNA extraction from samples was performed using the
QIAamp blood kit (Qiagen, Courtaboeuf, France). For HHV-6
genotyping, a nested PCRwas used to amplify a 492 bp fragment
on the U31 gene using the outer primers H6/594 (50 -TTA ACG
GTC GCG TTC TAA CC-30) and H6/1809 (50 -ACG CCT CGT
TGA ATA CTT CG-30) and the inner primers H6/772 (50 -AAG
AAG GCTATC ACT TAG ACACGG-30) and H6/1263 (50 -TTA
GGA TAA GAA GCT CGG CG-30). This fragment included a
HindIII restriction site for HHV-6 type B, absent in type A.
Viral infections are suggested to play a role in some drug-in-
duced eruptions. This is illustrated by the well-known ampicil-
lin-induced eruption in Epstein-Barr virus mononucleosis
syndrome. Our report demonstrates HHV-6 viremia of short
time duration at the beginning of the DRESS.Tohyama et al pre-
viously reported isolation of HHV-6 from peripheral blood
mononuclear cells in a patient with sulfasalazine-induced DRESS
(Pirmohamed et al, 2001). Isolation of HHV-6 preceded increase
in anti-HHV-6 IgG titers from 1/160 to 1/1280, 8 d later, and no
anti-HHV-6 IgM antibody was detected (Tohyama et al, 1998).
Detection of HHV-6 DNA in cell-free serum implies replica-
tion of HHV-6 in this patient. The quanti¢cation of the HHV-6
viral load brings new data to document the association of active
HHV-6 infection with DRESS. This may represent either a pri-
mary infection or a reactivation of HHV-6. We did not have
previous serum of our patient to identify the presence of anti-
HHV-6 IgG antibodies before. A primary infection or reinfection
cannot be excluded considering the very high level of viral load.
But we think that a selective reactivation of HHV-6 with a
strong replication is the most probable explanation in this
case and others. HHV-6 is the paradigm of opportunistic infec-
tious agent that may reactivate in some conditions. HHV-6
can infect a broad range of human cells: CD4 lymphocytes,
macrophages, dendritic cells, epithelial cells, ¢broblasts, and bone
marrow progenitors. But HHV-6 replication is only demon-
strated in activated CD4 lymphocytes. After primary infection,
reactivation or reinfection may occur in the case of immune dys-
regulation or de¢ciency. Selective replication of HHV-6 was also
reported in critically ill nonimmunocompromised patients
(Razonable et al, 2002). Recently, HHV-6 reactivation was also
demonstrated in pityriasis rosea patients (Watanabe et al, 2002). It
may be proposed that on a genetic background some drugs may
induce the production of reactive metabolites that may provoke
HHV-6 reactivation and propagation by the way of cytokine pro-
duction. It was demonstrated that activation of CD4þ lympho-
cytes with interleukin-2 was essential for propagation of HHV-6
in vitro. Recently the frequency of HLA-DR3 and HLA-DQ2
was found to be increased in a group of severe DRESS induced
by carbamazepine (p¼ 0.01; odds ratio 3.3, and p¼ 0.04, odds
ratio 2.7, respectively) (Pirmohamed et al, 2001). Interestingly
genotyping of this patient revealed that he was HLA-DR3
(DRB1n0301) and HLA-DQ2 (DQB1n0201) positive.
The role of HHV-6 may be not limited to the initial develop-
ment of DRESS. HHV-6 replication can lead to systemic viral
dissemination to target organs. HHV-6 may also be directly im-
plicated in systemic manifestations in DRESS. Recently, we and
others reported HHV-6 encephalitis associated with DRESS sug-
gesting that HHV-6 may be responsible for systemic manifestations
such as hepatitis, pancreatitis, and intestinal or meningo-
encephalitis (Descamps et al, 2003).
The link between drug reaction and HHV-6 viral infection
could suggest a new therapeutic approach of drug reactions with
antiviral agents. For instance HHV-6 U69 gene product is a func-
tional homolog of the human cytomegalovirus UL97 gene and
confers sensitivity of HHV-6 infected cells to antiviral drugs such
as ganciclovir (Gri⁄ths et al, 2000).Valganciclovir, a new oral de-
rivative of ganciclovir that is better tolerated than ganciclovir,
could be used in DRESS patients.
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